• BioAtla posted GAAP net income of USD 452,000, swinging from a GAAP net loss of USD 18.71 million a year earlier.
• Revenue was USD 6.5 million, compared with no revenue a year earlier, driven by payments under the Context License Agreement amendment.
• R&D expense fell 75.58% to USD 3.34 million, mainly on completion of Phase 2 trials and lower personnel costs after a March 2026 workforce cut.
• G&A expense dropped 40.95% to USD 2.93 million, reflecting lower personnel and professional fees, partly offset by higher advisor fees.
• Cash and cash equivalents totaled USD 1.5 million at June 30, 2026, with management citing substantial doubt about going-concern ability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioAtla Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-349542), on August 13, 2026, and is solely responsible for the information contained therein.